Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia
H Inaba, CH Pui - Journal of clinical medicine, 2021 - mdpi.com
The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …
during the last five decades. Such improvements were made possible by the incorporation of …
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
A Zhao, H Zhou, J Yang, M Li, T Niu - Signal Transduction and Targeted …, 2023 - nature.com
Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …
been rising in recent decades. The clinical and molecular features of hematologic …
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities
TH Tran, SP Hunger - Seminars in cancer biology, 2022 - Elsevier
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma …
L Pommert, ES Schafer, J Malvar… - American journal of …, 2022 - Wiley Online Library
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML)
remain dismal. Epigenetic changes can result in gene expression alterations which are …
remain dismal. Epigenetic changes can result in gene expression alterations which are …
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
J Ru, Y Wang, Z Li, J Wang, C Ren, J Zhang - European Journal of …, 2023 - Elsevier
Histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-l-lysine side chains in
histones and non-histones, which are key to epigenetic regulation in humans. Targeting …
histones and non-histones, which are key to epigenetic regulation in humans. Targeting …
The DNA methylation landscape of hematological malignancies: an update
P Blecua, L Martinez‐Verbo, M Esteller - Molecular Oncology, 2020 - Wiley Online Library
The rapid advances in high‐throughput sequencing technologies have made it more evident
that epigenetic modifications orchestrate a plethora of complex biological processes. During …
that epigenetic modifications orchestrate a plethora of complex biological processes. During …
Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?
Epigenetics is the study of heritable changes in gene expression or function without altering
the DNA sequence. Important factors are part of epigenetic events, such as methylation …
the DNA sequence. Important factors are part of epigenetic events, such as methylation …
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
A Kumar, L Emdad, PB Fisher, SK Das - Advances in Cancer Research, 2023 - Elsevier
Cancer cells display pervasive changes in DNA methylation, disrupted patterns of histone
posttranslational modification, chromatin composition or organization and regulatory …
posttranslational modification, chromatin composition or organization and regulatory …
Genetic and epigenetic targeting therapy for pediatric acute lymphoblastic leukemia
H Xu, H Yu, R **, X Wu, H Chen - Cells, 2021 - mdpi.com
Acute lymphoblastic leukemia is the most common malignancy in children and is
characterized by numerous genetic and epigenetic abnormalities. Epigenetic mechanisms …
characterized by numerous genetic and epigenetic abnormalities. Epigenetic mechanisms …
Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma
S Demir, N Razizadeh, E Indersie… - Hepatology …, 2024 - journals.lww.com
Background: As the variable clinical outcome of patients with hepatoblastoma (HB) cannot
be explained by genetics alone, the identification of drugs with the potential to effectively …
be explained by genetics alone, the identification of drugs with the potential to effectively …